Sergey O. Tcherniuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sergey O. Tcherniuk has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Aldrian Gudrun
Centre de Recherche de Biochimie Macromoléculaire, Centre National de la Recherche Scientifique (CNRS), Montpellier, France
1 shared publicationAnatoly I. Potopalsky
Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine (NAN Ukraine), Kiev, Ukraine
1 shared publicationBastien Herman
Institut de Biologie Structurale, Centre National de la Recherche Scientifique (CNRS), Grenoble, France
1 shared publicationJadwiga Chroboczek
Institut de Biologie Structurale, Centre National de la Recherche Scientifique (CNRS), Grenoble, France
1 shared publication
Latest Publications
- Open Access
- 7 March 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e57461
Amitozyn Impairs Chromosome Segregation and Induces Apoptosis via Mitotic Checkpoint Activation
Amitozyn (Am) is a semi-synthetic drug produced by the alkylation of major celandine (Chelidonium majus L.) alkaloids with the organophosphorous compound N,N’N’-triethylenethiophosphoramide (ThioTEPA). We show here that the treatment of living cells with Am reversibly perturbs the microtubule cytoskeleton, provoking a dose-dependent cell arrest in the M phase. Am changed the dynamics of tubulin polymerization in vitro, promoted the appearance of aberrant mitotic phenotypes in HeLa cells and induced apoptosis by the activation of caspase-9, caspase-3 and PARP, without inducing DNA breaks. Am treatment of HeLa cells induced changes in the phosphorylation of the growth suppressor pRb that coincided with maximum mitotic index. The dose-dependent and reversible anti-proliferative effect of Am was observed in several transformed cell lines. Importantly, the drug was also efficient against multidrug-resistant, paclitaxel-resistant or p53-deficient cells. Our results thus open the way to further pre-clinical evaluation of Am.
- 7 March 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (3) , e57461
Open AccessAmitozyn Impairs Chromosome Segregation and Induces Apoptosis via Mitotic Checkpoint Activation
Amitozyn (Am) is a semi-synthetic drug produced by the alkylation of major celandine (Chelidonium majus L.) alkaloids with the organophosphorous compound N,N’N’-triethylenethiophosphoramide (ThioTEPA). We show here that the treatment of living cells with Am reversibly perturbs the microtubule cytoskeleton, provoking a dose-dependent cell arrest in the M phase. Am changed the dynamics of tubulin polymerization in vitro, promoted the appearance of aberrant mitotic phenotypes in HeLa cells and induced apoptosis by the activation of caspase-9, caspase-3 and PARP, without inducing DNA breaks. Am treatment of HeLa cells induced changes in the phosphorylation of the growth suppressor pRb that coincided with maximum mitotic index. The dose-dependent and reversible anti-proliferative effect of Am was observed in several transformed cell lines. Importantly, the drug was also efficient against multidrug-resistant, paclitaxel-resistant or p53-deficient cells. Our results thus open the way to further pre-clinical evaluation of Am.